PMID- 9269790
OWN - NLM
STAT- MEDLINE
DCOM- 19970924
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 90
IP  - 4
DP  - 1997 Aug 15
TI  - Allogeneic peripheral blood progenitor cell transplantation in a murine model: 
      evidence for an improved graft-versus-leukemia effect.
PG  - 1694-700
AB  - Peripheral blood progenitor cells (PBPCs) are increasingly being used to replace 
      bone marrow cells (BMCs) as a source of hematopoietic stem cells also in the 
      field of allogeneic transplantation. Whereas it is well known that PBPC grafts 
      and BM differ significantly in progenitor cell content and lymphocyte dose, the 
      clinical consequences of these differences with respect to engraftment, 
      graft-versus-host disease (GVHD), and the graft-versus-leukemia (GVL) effect are 
      more difficult to assess. We present a murine model that allows us to evaluate 
      engraftment, GVHD, and GVL effect of allogeneic PBPC transplantation (PBPCT). 
      Balb/c mice (H-2d) served as recipients. Donors were major histocompatibility 
      complex-matched DBA/2 mice or syngeneic Balb/c mice, respectively. Experiments 
      with increasing numbers of BMCs or Filgastrim-mobilized PBPCs showed that the 
      number of progenitor cells in the graft was correlated with the probability to 
      engraft, irrespective of the graft type. With identically high cell numbers 
      transferred (1 x 10(9) nucleated cells/kg body weight [BW]), the mortality rates 
      due to GVHD (25%) were about the same after allogeneic BM transplantation (BMT) 
      and allogeneic PBPCT, although PBPC grafts contained four times more CD3+ T cells 
      as compared with BM grafts (6.2 x 10(8) v 1.4 x 10(8)/kg BW). For investigation 
      of GVL activity, Balb/c recipients were injected with syngeneic cells of the 
      B-lymphocytic leukemia cell line A20 2 days before transplantation. After total 
      body irradiation to a dose of 7.5 Gy, 1 x 10(9)/kg BW Balb/c PBPCs, DBA BMCs, or 
      DBA PBPCs were infused. The relapse rates observed were 80% after syngeneic PBPCT 
      (n = 22), 60% after allogeneic BMT (n = 23), and 34% after allogeneic PBPCT (n = 
      26) (allogeneic BMT v PBPCT, P = .032). We conclude that transplantation of 
      allogeneic PBPCs instead of BM may enhance the GVL effect without an increase of 
      GVHD.
FAU - Glass, B
AU  - Glass B
AD  - 2nd Department of Internal Medicine and Institute for Immunology, 
      Christian-Albrechts-University of Kiel, Germany.
FAU - Uharek, L
AU  - Uharek L
FAU - Zeis, M
AU  - Zeis M
FAU - Dreger, P
AU  - Dreger P
FAU - Loffler, H
AU  - Loffler H
FAU - Steinmann, J
AU  - Steinmann J
FAU - Schmitz, N
AU  - Schmitz N
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
MH  - Animals
MH  - Bone Marrow Transplantation
MH  - Cell Separation
MH  - Flow Cytometry
MH  - Graft vs Host Reaction
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Leukemia, Experimental/*therapy
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred DBA
MH  - Transplantation, Homologous
EDAT- 1997/08/15 00:00
MHDA- 1997/08/15 00:01
CRDT- 1997/08/15 00:00
PHST- 1997/08/15 00:00 [pubmed]
PHST- 1997/08/15 00:01 [medline]
PHST- 1997/08/15 00:00 [entrez]
AID - S0006-4971(20)58088-9 [pii]
PST - ppublish
SO  - Blood. 1997 Aug 15;90(4):1694-700.